The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study
Abstract
BACKGROUND: Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles. METHODS: In this European, multicenter, open-label, 96-week study, antiretroviral-naive adult subjects with human immunodeficiency virus (HIV) infection were randomized to receive either abacavir-lamivudine or tenofovir-emtricitabine with efavirenz. Primary analyses were conducted after 48 weeks of treatment. Bone mineral density (BMD), a powered secondary end point, was assessed by dual energy x-ray absorptiometry. Bone turnover markers (osteocalcin, procollagen 1 N-terminal propeptide, bone specific alkaline phosphatase, and type 1 collagen cross-linked C telopeptide [CTx]) were assessed in an exploratory analysis. RESULTS: A total of 385 subjects were enrolled in the study. BMD loss was observed in both treatment groups, with a significant difference in the change from baseline in both total hip (abacavir-lamivudine group, -1.9%; tenofovir-emtricitabine group, -3.6%; P < .001) and lumbar spine (abacavir-lamivudine group, -1.6%; tenofovir-emtricitabine group, -2.4%; P = .036). BMD loss of >or=6% was more common in the tenofovir-emtricitabine group (13% of the tenofovir-emtricitabine group vs 3% of the abacavir-lamivudine group had a loss of >or=6% in the hip; 15% vs 5% had a loss of >or=6% in the spine). Bone turnover markers increased in both treatment groups over the first 24 weeks, stabilizing or decreasing thereafter. Increases in all markers were significantly greater in the tenofovir-emtricitabine treatment group than in the abacavir-lamivudine group at week 24. All but CTx remained significantly different at week 48 (eg, osteocalcin: abacavir-lamivudine group, +8.07 mg/L; tenofovir-emtricitabine group, +11.92 mg/L; P < .001). CONCLUSIONS: This study demonstrated the impact of first-line treatment regimens on bone. Greater increases in bone turnover and decreases in BMD were observed in subjects treated with tenofovir-emtricitabine than were observed in subjects treated with abacavir-lamivudine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
Self-citationGallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341 · cited 2×
“Loss of BMD has been reported among HIV-infected patients who initiated ART (specifically, within the first 24–48 weeks of ART), irrespective of the regimen used [13, 17, 29], although initial changes may stabilize after 1 year of treatment [9, 10, 15].”
BackgroundTreatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Khosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review
Brown, T. T., & Qaqish, R. B. (2006) · AIDS · doi:10.1097/qad.0b013e32801022eb · Cited by 925
Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 737
Baim, S., Leonard, M. B., Bianchi, M.-L., Hans, D. B., Kalkwarf, H. J., Langman, C. B., & Rauch, F. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.002 · Cited by 707
Bone Mineral Density Changes during the Menopause Transition in a Multiethnic Cohort of Women
Finkelstein, J. S., Brockwell, S. E., Mehta, V., Greendale, G. A., Sowers, M. R., Ettinger, B., Lo, J. C., Johnston, J. M., Cauley, J. A., Danielson, M. E., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1876 · Cited by 597
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
Tebas, P., Powderly, W. G., Claxton, S., Marin, D., Tantisiriwat, W., Teitelbaum, S. L., & Yarasheski, K. E. (2000) · AIDS · doi:10.1097/00002030-200003100-00005 · Cited by 532
Cited by
Sax, P. E., Wohl, D., Yin, M. T., Post, F., DeJesus, E., Saag, M., Pozniak, A., Thompson, M., Podzamczer, D., Molina, J. M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60616-x · Cited by 601
McComsey, G. A., Kitch, D., Daar, E. S., Tierney, C., Jahed, N. C., Tebas, P., Myers, L., Melbourne, K., Ha, B., & Sax, P. E. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir188 · Cited by 495
Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Mills, A., Arribas, J. R., Andrade-Villanueva, J., DiPerri, G., Van Lunzen, J., Koenig, E., Elion, R., Cavassini, M., Madruga, J. V., Brunetta, J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00348-5 · Cited by 302
Self-citationWeitzmann, M. N. (2013) · Scientifica · doi:10.1155/2013/125705 · Cited by 259
Grant, P. M., & Cotter, A. G. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000248 · Cited by 165
Gill, U. S., Zissimopoulos, A., Al-Shamma, S., Burke, K., McPhail, M. J. W., Barr, D. A., Kallis, Y. N., Marley, R. T. C., Kooner, P., Foster, G. R., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu471 · Cited by 93
Bernardino, J. I., Mocroft, A., Mallon, P. W., Wallet, C., Gerstoft, J., Russell, C., Reiss, P., Katlama, C., De Wit, S., Richert, L., et al. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00181-2 · Cited by 76
Self-citation
Metadata
- Authors
- Stellbrink, H., Orkin, C., Arribas, J. R., Compston, J., Gerstoft, J., Van Wijngaerden, E., Lazzarin, A., Rizzardini, G., Sprenger, H. G., Lambert, J., Sture, G., Leather, D., Hughes, S., Zucchi, P., & Pearce, H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10-15
- Volume
- 51
- Issue
- 8
- Pages
- 963-972
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2144658061
- Cited by
- 405
- References
- 31
- FWCI
- 32.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.